Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

HTA guidance from NICE, the SMC and the AWMSG

Celgene has scored a positive recommendation from England’s cost-effectiveness watchdog NICE for Revlimid in follicular lymphoma, chalking up another indication.

Janssen scores another expansion for new Darzalex combination in the US

Janssen scores another expansion for new Darzalex combination in the US It also has an approval for another combination regimen made up of Darzalex, Celgene’s Revlimid (lenalidomide) and dexamethasone, for the treatment of newly diagnosed multiple myeloma patients who are ineligible

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Bristol-Myers Squibb’s revenues rise on Celgene acquisition BMS’ biggest seller was its multiple myeloma therapy Revlimid (lenalidomide), which it added to its portfolio following the Celgene acquisition.

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa The anti-CD38 antibody is an option for patients who have been treated with at least two prior therapies, including BMS’ Revlimid (lenalidomide) and a proteasome inhibitor such as Takeda’s

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma The 750-patrient ELOQUENT-1 trial showed that adding Empliciti (elotuzumab) to background treatment with BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone didn’t extend the time patients with newly-diagnosed ... That said, “Empliciti,

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics